Stephanie Holland

News

Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer

07/17/2024

Stephanie Holland ;

Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.

Results from the SWOG S127 study...

07/17/2024

Oncology

News

Addition of Atezolizumab to Chemotherapy Did Not Improve Overall Survival Among Patients With Early Relapsing Unresectable Advanced Triple-Negative Breast Cancer

07/16/2024

Stephanie Holland ;

Results from the phase 3 IMpassion132 study demonstrated that the addition of atezolizumab to chemotherapy did not improve overall survival among patients with early relapsing unresectable advanced or metastatic triple-negative breast cancer.

Results from the phase 3...

07/16/2024

Oncology

News

Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer

07/16/2024

Stephanie Holland ;

According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.

According to results from the...

07/16/2024

Oncology

News

Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer

07/15/2024

Stephanie Holland ;

Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.

Results from the phase 3...

07/15/2024

Oncology

News

First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

07/11/2024

Stephanie Holland ;

Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...

Results from the phase 2 RIGHT...

07/11/2024

Oncology

News

Adjuvant Dabrafenib Plus Trametinib Improved Long-Term Survival Among Patients With Advanced-Stage Melanoma Harboring BRAF V600 Mutations

07/11/2024

Stephanie Holland ;

According to final analysis results from the phase 3 COMBI-AD trial, adjuvant dabrafenib plus trametinib improved long-term recurrence-free and distant metastasis-free survival compared to placebo among patients with stage 3 melanoma...

According to final analysis...

07/11/2024

Oncology

News

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer

07/11/2024

Stephanie Holland ;

Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...

Final analysis results from the...

07/11/2024

Oncology

News

Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer

07/08/2024

Stephanie Holland ;

Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.

Long-term results from the phase...

07/08/2024

Oncology

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland ;

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

Conference Coverage

Erdafitinib Shows Promising Clinical Efficacy, Safety Among Pre-Treated Patients With FGFR-Altered Non-Small Cell Lung Cancer

06/26/2024

Stephanie Holland ;

According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.

According to results from the...

06/26/2024

Oncology